Literature DB >> 21653966

An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines.

Helen Saxenian1, Santiago Cornejo, Kira Thorien, Robert Hecht, Nina Schwalbe.   

Abstract

Immunization is one of the "best buys" in global health. However, for the poorest countries, even modest expenditures may be out of reach. The GAVI Alliance is a public-private partnership created to help the poorest countries introduce new vaccines. Since 2008 GAVI has required that countries cover a share of the cost of vaccines introduced with GAVI support. To determine how much countries can contribute to the cost of vaccines--without displacing spending on other essential programs--we analyzed their fiscal capacity to contribute to the purchase of vaccines over the coming decade. For low-income countries, external financing will be required to purchase vaccines supported by GAVI, so co-financing needs to be modest. Relatively better-off "intermediate" countries could support initially modest but gradually increasing co-financing levels. The countries soon to graduate from GAVI can generally afford to follow a rapid path to self-sufficiency. Co-financing for these countries needs to ramp up so that national budgets fully cover the costs of the new generation of vaccines once GAVI support ends.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653966     DOI: 10.1377/hlthaff.2011.0332

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  13 in total

1.  Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants.

Authors:  Ulla Kou Griffiths; Andrew Clark; Rana Hajjeh
Journal:  J Pediatr       Date:  2013-07       Impact factor: 4.406

Review 2.  Challenges for nationwide vaccine delivery in African countries.

Authors:  Mario Songane
Journal:  Int J Health Econ Manag       Date:  2017-10-19

3.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

4.  The future of routine immunization in the developing world: challenges and opportunities.

Authors:  Angela K Shen; Rebecca Fields; Mike McQuestion
Journal:  Glob Health Sci Pract       Date:  2014-12-10

5.  State of equity: childhood immunization in the World Health Organization African Region.

Authors:  Rebecca Mary Casey; Lee McCalla Hampton; Blanche-Philomene Melanga Anya; Marta Gacic-Dobo; Mamadou Saliou Diallo; Aaron Stuart Wallace
Journal:  Pan Afr Med J       Date:  2017-06-21

6.  Insights for the future of health system partnerships in low- and middle-income countries: a systematic literature review.

Authors:  Simone Fanelli; Fiorella Pia Salvatore; Gianluigi De Pascale; Nicola Faccilongo
Journal:  BMC Health Serv Res       Date:  2020-06-22       Impact factor: 2.655

7.  Balancing safety, efficacy and cost: Improving rotavirus vaccine adoption in low- and middle-income countries.

Authors:  Anant Bhan; Shane K Green
Journal:  J Glob Health       Date:  2011-12       Impact factor: 4.413

8.  Financing HIV programming: how much should low- and middle-income countries and their donors pay?

Authors:  Omar Galárraga; Veronika J Wirtz; Yared Santa-Ana-Tellez; Eline L Korenromp
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

9.  Costs of introducing pneumococcal, rotavirus and a second dose of measles vaccine into the Zambian immunisation programme: Are expansions sustainable?

Authors:  Ulla Kou Griffiths; Fiammetta Maria Bozzani; Collins Chansa; Anthony Kinghorn; Penelope Kalesha-Masumbu; Cheryl Rudd; Roma Chilengi; Logan Brenzel; Carl Schutte
Journal:  Vaccine       Date:  2016-06-28       Impact factor: 3.641

10.  Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries.

Authors:  Helen Saxenian; Robert Hecht; Miloud Kaddar; Sarah Schmitt; Theresa Ryckman; Santiago Cornejo
Journal:  Health Policy Plan       Date:  2014-02-08       Impact factor: 3.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.